Glucocorticoid Receptor Suppresses Tumor Formation by Ensuring Accurate Chromosome Segregation During Mitosis
|
By LabMedica International staff writers Posted on 20 Apr 2015 |

Image: Electrophoretic data confirmed disruption of mitosis in cells lacking GR (Photo courtesy of the University of Manchester).
A team of British molecular biologists has defined the mechanism by which glucocorticoid receptor (GR) regulates the process of mitosis to prevent errors in cell division that could lead to tumor formation.
GR is a member of the nuclear receptor superfamily, which controls programs regulating cell proliferation, differentiation, and apoptosis. GR is expressed in almost every cell in the body and regulates genes controlling development, metabolism, and immune response. As the receptor gene is expressed in several forms, it has many different effects in various parts of the body. Unbound receptor resides in the cytosol of the cell. Binding of GR to glucocorticoids triggers its primary mechanism of action, which is the regulation of gene transcription. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol (by preventing the translocation of other transcription factors from the cytosol into the nucleus).
Investigators at the University of Manchester (United Kingdom) identified an additional role for GR related to regulation of cell division. They discovered that specifically modified GR species accumulated at the mitotic spindle during mitosis in a distribution that overlapped with enzymes of the Aurora kinase family. They found that Aurora A was required to mediate mitosis-driven GR phosphorylation, but not recruitment of GR to the spindle. GR was necessary for mitotic progression, with increased time to complete mitosis, frequency of mitotic aberrations, and death in mitosis observed following GR knockdown. Complementation studies revealed an essential role for the GR ligand-binding domain, but no clear requirement for ligand binding in regulating chromosome segregation.
GR haploinsufficient mice (animals with only a single functional copy of the GR gene that did not produce enough of the gene product to bring about the wild-type condition) had an increased incidence of tumor formation, and these tumors were further depleted for GR, implying additional GR loss as a consequence of cell transformation. Reduced GR expression was identified in a panel of human liver, lung, prostate, colon, and breast cancers.
The unexpected role for the GR in promoting accurate chromosome segregation during mitosis marked GR as an authentic tumor suppressor gene. "Cancer is caused by cell division going wrong, but no one has previously looked at the role GR has to play in this process," said senior author Dr. David Ray, professor of human development at the University of Manchester. "It is now clear that it is vital."
The study was published in the April 6, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of Manchester
GR is a member of the nuclear receptor superfamily, which controls programs regulating cell proliferation, differentiation, and apoptosis. GR is expressed in almost every cell in the body and regulates genes controlling development, metabolism, and immune response. As the receptor gene is expressed in several forms, it has many different effects in various parts of the body. Unbound receptor resides in the cytosol of the cell. Binding of GR to glucocorticoids triggers its primary mechanism of action, which is the regulation of gene transcription. After the receptor is bound to glucocorticoid, the receptor-glucorticoid complex up-regulates the expression of anti-inflammatory proteins in the nucleus or represses the expression of pro-inflammatory proteins in the cytosol (by preventing the translocation of other transcription factors from the cytosol into the nucleus).
Investigators at the University of Manchester (United Kingdom) identified an additional role for GR related to regulation of cell division. They discovered that specifically modified GR species accumulated at the mitotic spindle during mitosis in a distribution that overlapped with enzymes of the Aurora kinase family. They found that Aurora A was required to mediate mitosis-driven GR phosphorylation, but not recruitment of GR to the spindle. GR was necessary for mitotic progression, with increased time to complete mitosis, frequency of mitotic aberrations, and death in mitosis observed following GR knockdown. Complementation studies revealed an essential role for the GR ligand-binding domain, but no clear requirement for ligand binding in regulating chromosome segregation.
GR haploinsufficient mice (animals with only a single functional copy of the GR gene that did not produce enough of the gene product to bring about the wild-type condition) had an increased incidence of tumor formation, and these tumors were further depleted for GR, implying additional GR loss as a consequence of cell transformation. Reduced GR expression was identified in a panel of human liver, lung, prostate, colon, and breast cancers.
The unexpected role for the GR in promoting accurate chromosome segregation during mitosis marked GR as an authentic tumor suppressor gene. "Cancer is caused by cell division going wrong, but no one has previously looked at the role GR has to play in this process," said senior author Dr. David Ray, professor of human development at the University of Manchester. "It is now clear that it is vital."
The study was published in the April 6, 2015, online edition of the journal Proceedings of the National Academy of Sciences of the United States of America (PNAS).
Related Links:
University of Manchester
Latest BioResearch News
- AI-Powered Genome Mapping Reveals New Layer of Alzheimer’s Disease Biology
- Genetic Variations Reveal Mechanisms Behind Sudden Cardiac Death Risk
- Immune Biomarkers Support Early Risk Stratification in Oral Precancer
- Global Genetic Map Identifies Regional Parkinson’s Variants to Support Diagnostics
- Breakthrough Genetic Map Advances Understanding of Bone Disorders
- Study Identifies Hereditary Subtype of Aggressive Prostate Cancer
- Gene Variants Linked to Pollution-Exacerbated Asthma
- Single-Cell Analysis Mapping Links Inflammation Response to Acute Myeloid Leukemia
- Study Reveals New Insights into Rare Blood Cancer Development
- New Findings Clarify Molecular Drivers of Rare Small Intestinal Cancer
- Lung Cancer Study Reveals Cellular Program Behind Therapy Resistance
- Tumor Genome Marker May Predict Treatment Benefit in Pediatric Cancers
- Lysosomal Gene Defect Linked to Severe Childhood Brain Disorders
- Genetic Testing Identifies Greater Inherited Sudden Cardiac Arrest Risk in Younger Individuals
- Hidden 'Jumping Gene' Variant Linked to Higher Pancreatic Cancer Risk
- Common White Blood Cells Produce Schizophrenia-Linked Protein
Channels
Clinical Chemistry
view channel
Blood Protein Panel Predicts Timing of ALS Symptom Onset
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease in which clinical signs often emerge only after substantial motor neuron injury has already occurred, complicating timely intervention.... Read more
Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers
Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read moreMolecular Diagnostics
view channel
Genomic Fingerprints Reveal Early Chemotherapy Resistance in Childhood Cancer
Chemotherapy remains central to treating childhood cancers, yet its toxic effects can injure healthy tissues, and some tumors later relapse or spread. Clinicians have lacked early molecular markers that... Read more
Blood Gene Expression Fluctuates More Than Expected Over Time
Blood-based gene expression is widely used to explore disease biology, but temporal variability can complicate interpretation of single time-point measurements. Seasonal shifts, time of day, and subclinical... Read more
Genomic Test Helps Early Breast Cancer Patients Avoid Chemotherapy
Adjuvant chemotherapy decisions in early breast cancer can expose many patients to toxicities without clear benefit when clinical factors alone do not precisely predict recurrence risk. Clinicians therefore... Read more
Residual Disease Test Predicts Merkel Cell Carcinoma Recurrence Earlier Than Antibody Assay
Merkel cell carcinoma is a rare, aggressive skin cancer with a substantial risk of relapse, occurring in about 40% of patients. Surveillance remains challenging because widely used serologic monitoring... Read moreHematology
view channel
Spectral Flow Cytometry Assay Enhances MRD Detection in Multiple Myeloma
imal residual disease (MRD) monitoring is pivotal in multiple myeloma, where persistent malignant plasma cells drive relapse risk and help guide therapy decisions. In the United States, approximately 202,000... Read more
New Marker Helps Detect Aggressive Multiple Myeloma Earlier
Multiple myeloma is an incurable malignancy of plasma cells and the second most common blood cancer worldwide, with more than 188,000 new cases each year. Although therapies have advanced, most patients... Read moreImmunology
view channel
Study Reveals Immune Mechanism Driving Severe COVID-19 Progression
Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more
Antibody Profiling Identifies Preclinical Inflammatory Bowel Disease Years Before Diagnosis
Inflammatory bowel disease often develops after a prolonged symptom-free period, complicating timely recognition and clinical intervention. Limited understanding of immune activity during this silent phase... Read more
Ultrasensitive Blood Test Detects Sjögren’s Signature Years Before Diagnosis
Sjögren’s disease is a common autoimmune condition that can be difficult to recognize early, leading to delayed diagnosis and persistent symptom burden. It affects around half a million people in the UK... Read more
New Assays Expand Cytokine Testing for Transplant and Immunocompromised Patients
Eurofins Viracor has introduced three plasma-based assays—CXCL9 (Test Code 33607), CXCL10 (Test Code 33609), and interleukin-18 (IL-18) (Test Code 33611)—expanding its immunology testing menu for transplant... Read moreMicrobiology
view channel
High-Throughput Automated Platform to Advance Latent Tuberculosis Testing
Testing for tuberculosis remains a persistent global need, with demand driven by immigration screening, pre-treatment evaluation for immunosuppressive therapies, and public health programs.... Read more
Expanded Diagnostics and Therapies Target Rising Gonorrhea Resistance
Drug-resistant Neisseria gonorrhoeae is straining current treatment protocols and elevating the risk of complications across sexual health services. More than 500,000 cases are reported each year in the... Read morePathology
view channel
PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers
Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
AI Digital Pathology Platform Standardizes IHC Scoring in Breast Cancer
Breast cancer diagnostic workflows increasingly depend on accurate quantification of immunohistochemical biomarkers to guide therapy selection, yet manual scoring can be variable and time-consuming.... Read moreTechnology
view channel
Training Device Improves Accuracy of Pooled Molecular Diagnostics
High-throughput molecular diagnostics have transformed infectious disease detection, but many workflows remain difficult to execute accurately without extensive training. Sample pooling can cut per‑test... Read more
New CE-Certified Software Advances Whole-Genome Cancer Testing
European hospitals are increasingly using comprehensive tumor genomics to guide therapy, but routine whole genome sequencing (WGS) requires validated, regulation-compliant workflows. A newly CE-certified... Read more
National Rare Disease Registry Standardizes Genetic and Clinical Data for Coordinated Care
Rare diseases collectively impose a significant clinical burden despite their individual rarity, often involving multisystem presentations and prolonged diagnostic journeys. Limited specialist expertise... Read moreIndustry
view channel
Collaboration Advances Sputum-Based Diagnostics for Asthma and COPD
Asthma and chronic obstructive pulmonary disease are highly prevalent inflammatory airway conditions, affecting more than 40 million Americans and more than 650 million people worldwide.... Read more








